https://www.prognyx.com/blog/astrazeneca-s-cldn18-2-adc-won-a-late-stage-trial-with-a-caveat-and-the-caveat-iPrognyxen2026-07-28Sonesitatug vedotin won overall survival in CLARITY-Gastric01 and missed its PFS co-primary — and moved the CLDN18.2 bar to 25%